Genetic Susceptibility in Dry Eye Disease: Immunogenetic Evidence, Current Limitations, and Future Directions.
7 affiliations
- 1Eye Clinic, Catania University, Policlinico G. Rodolico, 95121 Catania, Italy.
- 2Department of Ophthalmology, University Hospital of Udine, 33100 Udine, Italy.
- 3Department of Medicine, Surgery and Health Sciences, University of Trieste, 34129 Trieste, Italy.
- 4Department of Medicine and Surgery, University of Enna "Kore", Piazza dell'Università, 94100 Enna, Italy.
- 5Mediterranean Foundation "G.B. Morgagni", 95125 Catania, Italy.
- 6Department of Biomedical Sciences, University of Messina, 98122 Messina, Italy.
- 7Faculty of Medicine, Andrzej Frycz Modrzewski Krakòw University, Gustawa Herlinga-Grudzińskiego 1, 30-705 Krakow, Poland.
Abstract
Dry eye disease is a multifactorial disorder which is heterogeneous in nature, caused by interactions among ocular surface abnormalities, systemic diseases, environmental factors and host susceptibility. The inherited variation related to the pathophysiology of dry eye disease is not very well characterized, but known mechanisms include inflammation, tear film instability, neurosensory dysfunction and lacrimal and meibomian gland changes. Studies exploring the contribution of genetics suggest that dry eye disease (DED) and specific ocular surface endophenotypes are heritable. Candidate-gene and human leukocyte antigen association studies have reinforced contributions from pathways associated with innate and adaptive immunity, inflammatory regulation and neural function, and glandular homeostasis, but many associations require replication in larger, more diverse populations. Genome-wide association studies and biobank-based assessments have recently begun to shed light on the polygenic architecture of Dry Eye Disease (DED) and its genetic overlap with other related conditions worldwide. This paper evaluates critically the current evidence on DED heritability, candidate susceptibility genes, HLA associations, genome-wide signals, polygenic risk models and genetic pleiotropy. It will cover how transcriptomic, epigenomic, and single-cell approaches can link inherited susceptibility loci to disease-relevant cell states and molecular pathways across the ocular surface unit, including the cornea, conjunctiva, lacrimal gland, and meibomian glands. The study would stress phenotypic heterogeneity, ancestry-related limitations, and inconsistent diagnostic definitions. In the end, we will evaluate opportunities and existing constraints in the incorporation of genomic information with clinical endophenotypes and environmental exposures to support risk stratification, biomarker discovery, identification of therapeutic targets, and the development of future ocular surface precision medicine.
Related
- BMP-2 in Orthopedic Trauma and Limb Reconstruction: Current Evidence, Limitations, and Future Directions
- Cell-free DNA fragmentomics and epigenomic profiling in hematologic malignancies: current evidence, translational limitations, and future directions
- Telomere length as a systemic aging-related susceptibility marker for trigeminal neuralgia: Genetic evidence from mendelian randomization
- Current classification systems in slipped capital femoral epiphysis: Clinical relevance, limitations, and future directions
- Vitamin D–VDR Signaling Across Thyroid Disorders: A Systematic Review of Molecular Mechanisms, Autoimmunity, Genetic Susceptibility, Experimental Evidence and Therapeutic Translation
BibTeX
@article{capobianco2026genetic,
title = {{Genetic Susceptibility in Dry Eye Disease: Immunogenetic Evidence, Current Limitations, and Future Directions.}},
author = {Matteo Capobianco and Marco Zeppieri and Francesco Cappellani and Caterina Gagliano and Roberto Angelo Consoli and Sonia Mangiagli and Anna M Roszkowska},
journal = {Genes},
year = {2026},
month = oct,
doi = {10.3390/genes17101253},
url = {https://europepmc.org/article/MED/42938367},
note = {CC BY},
}
RIS
TY - JOUR
TI - Genetic Susceptibility in Dry Eye Disease: Immunogenetic Evidence, Current Limitations, and Future Directions.
AU - Matteo Capobianco
AU - Marco Zeppieri
AU - Francesco Cappellani
AU - Caterina Gagliano
AU - Roberto Angelo Consoli
AU - Sonia Mangiagli
AU - Anna M Roszkowska
PY - 2026
DA - 2026/10/10
JO - Genes
DO - 10.3390/genes17101253
UR - https://europepmc.org/article/MED/42938367
AB - Dry eye disease is a multifactorial disorder which is heterogeneous in nature, caused by interactions among ocular surface abnormalities, systemic diseases, environmental factors and host susceptibility. The inherited variation related to the pathophysiology of dry eye disease is not very well characterized, but known mechanisms include inflammation, tear film instability, neurosensory dysfunction and lacrimal and meibomian gland changes. Studies exploring the contribution of genetics suggest that dry eye disease (DED) and specific ocular surface endophenotypes are heritable. Candidate-gene and human leukocyte antigen association studies have reinforced contributions from pathways associated with innate and adaptive immunity, inflammatory regulation and neural function, and glandular homeostasis, but many associations require replication in larger, more diverse populations. Genome-wide association studies and biobank-based assessments have recently begun to shed light on the polygenic architecture of Dry Eye Disease (DED) and its genetic overlap with other related conditions worldwide. This paper evaluates critically the current evidence on DED heritability, candidate susceptibility genes, HLA associations, genome-wide signals, polygenic risk models and genetic pleiotropy. It will cover how transcriptomic, epigenomic, and single-cell approaches can link inherited susceptibility loci to disease-relevant cell states and molecular pathways across the ocular surface unit, including the cornea, conjunctiva, lacrimal gland, and meibomian glands. The study would stress phenotypic heterogeneity, ancestry-related limitations, and inconsistent diagnostic definitions. In the end, we will evaluate opportunities and existing constraints in the incorporation of genomic information with clinical endophenotypes and environmental exposures to support risk stratification, biomarker discovery, identification of therapeutic targets, and the development of future ocular surface precision medicine.
SN - 2073-4425
ER -